display ongoing studies
summary
treatment
patients
method
baseline characteristics
risk of bias
references
asymptomatic COVID case confirmed COVID (any severity) confirmed Covid-19, from 1st dose hospitalization ICU admission infection (PCR positive symptomatic or not) mechanical ventilation severe COVID-19 occurrence symptomatic Covid-19 vaccine efficacy after dose 1 (and before dose 2)
overview
numeric
bar chart
forest plot
medians
figures
uncontrolled
O6
Study
Ref.
Design
studied treatment control treatment patients study risk of bias sample sizes
Results
COVID-19 prophylaxis (excluding children) meta-analysis Tartof NCT04848584 OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children), COVID-19 prophylaxis (excluding children) NA -/- suggested suggested 73 % decrease in confirmed COVID (any severity) suggested 91 % decrease in confirmed COVID (any severity) suggested 90 % decrease in hospitalization COVID-19 prophylaxis (children) meta-analysis kidCOVE (part 2) NCT04796896 RCT Spikevax (Moderna mRNA-1273 COVID-19 vaccine) placebo COVID-19 prophylaxis (children) NA 3005/997 suggested suggested 74 % decrease in confirmed COVID (any severity) suggested 88 % decrease in symptomatic Covid-19 press realease March 23,2022 : - interim analysis showed a robust neutralizing antibody response in both age groups (6 month -2 years and 2 years to 6 years) after a 25 µg two-dose primary series of mRNA-1273 along with a favorable safety profile.- Using the Phase 3 COVE study COVID-19 definition, vaccine efficacy in children 6 months to 2 years was 43.7% and vaccine efficacy was 37.5% in the 2 to under 6 years age group C4591001 (Adolescents 12-25) NCT04368728 RCT Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) some concern 1134/1130 suggested suggested 92 % decrease in confirmed Covid-19, from 1st dose with a moderate degree of certainty due to some concern in risk of bias suggested 97 % decrease in symptomatic Covid-19 with a moderate degree of certainty due to some concern in risk of bias teenCOVE (P203) (Adolescents 12-17Y) NCT04649151 RCT Spikevax (Moderna mRNA-1273 COVID-19 vaccine) placebo COVID-19 prophylaxis (children) some concern 2489/1243 suggested suggested 93 % decrease in confirmed COVID (any severity) with a moderate degree of certainty due to some concern in risk of bias Walter E.B. (Children <12 Years of Age) NCT04816643 RCT Comirnaty (tozinameran - Pfizer/BIONTECH) placebo COVID-19 prophylaxis (children) NA 1528/757 conclusif demonstrated 91 % decrease in confirmed COVID (any severity) (PE) Lutrick (PROTECT study) OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) NA -/- suggested suggested 92 % decrease in confirmed COVID (any severity) Klein ( VISION network) OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) NA -/- suggested suggested 92 % decrease in hospitalization suggested 46 % decrease in symptomatic Covid-19 suggested 38 % decrease in symptomatic Covid-19 Glatman-Freedman A OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) NA -/- suggested suggested 91 % decrease in confirmed COVID (any severity),confirmed COVID (any severity) June OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) NA 439079/863341 safety concern suggested 91 % decrease in confirmed Covid-19, from 1st dose suggested 99 % decrease in confirmed COVID (any severity) statistically significant 98.1-fold increase in infection (PCR positive symptomatic or not) statistically significant 90.1-fold increase in vaccine efficacy after dose 1 (and before dose 2) Reis OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) NA -/- suggested suggested 90 % decrease in confirmed COVID (any severity),confirmed COVID (any severity) suggested 93 % decrease in symptomatic Covid-19,symptomatic Covid-19 Olson (July to October) OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) NA -/- suggested suggested 95 % decrease in hospitalization Price OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) NA -/- suggested suggested 83 % decrease in hospitalization suggested 68 % decrease in hospitalization,hospitalization Veneti OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) NA -/- suggested suggested 91 % decrease in confirmed COVID (any severity) Olson (June to September) OBS Comirnaty (tozinameran - Pfizer/BIONTECH) control COVID-19 prophylaxis (children) NA -/- suggested suggested 91 % decrease in hospitalization,hospitalization
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).